HIV Articles
Back
	Weekly Oral Islatravir+MK-8507 (Ulonivirine NNRTI)       • Phase 2 Once-Weekly Dose Optimization for Ulonivirine in Combination with Islatravir 2 mg - (07/18/25)   • An Open-Label Phase 1 Study to Evaluate Drug Interactions Between Multiple Weekly Doses of Ulonivirine (MK-8507) and Single Doses of Islatravir in Adults Without HIV - (07/18/25)   • A Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate Extended Multiple Dosing of Ulonivirine (MK-8507) in Adults Without HIV - (07/18/25)   CROI: MODEL-INFORMED DOSE SELECTION FOR ISLATRAVIR/MK-8507 ORAL ONCE-WEEKLY PHASE 2B STUDY - (03/06/21)   CROI: NNRTI MK-8507 Selects V106 Mutations, Active Against Common NNRTI Mutations - (03/09/21)   CROI: RESISTANCE PROFILE OF MK-8507, A NOVEL NNRTI SUITABLE FOR WEEKLY ORAL HIV TREATMENT - (03/09/21)   GLASGOW: SINGLE DOSES OF MK-8507, A NOVEL HIV-1 NNRTI, REDUCED HIV VIRAL LOAD FOR AT LEAST A WEEK - (10/09/20)   A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)   2025-10-16 https://clinicaltrials.gov/study/NCT06891066   A Phase 2b, Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to Islatravir (ISL) and Ulonivirine (ULO) Once Weekly in Adults With HIV-1 Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) Once Daily           View Older Articles   Back to Top   www.natap.org